filgrastim


Also found in: Medical, Wikipedia.
Related to filgrastim: Sargramostim

fil·gras·tim

 (fĭl-grăs′təm)
n.
A recombinant form of granulocyte colony-stimulating factor, used as a drug to treat neutropenia especially as a result of chemotherapy, and in patients undergoing bone marrow transplantation.

[fil- (probably alteration of (neutro)phil) + gra(nulocyte) + stim(ulating).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

filgrastim

n filgrastim m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Filgrastim is used as a medication for treating low levels of blood neutrophils caused by chemotherapy, HIV/AIDS, radiation poisoning or some other unknown source.
We compared 2 products containing recombinant filgrastim: the biosimilar (Leucostim[R]; DONG-A Pharm, Daegu, South Korea) which was approved by Turkish Ministry of Health at 2009 and the original drug (Neupogen[R]; Roche, Mannheim, Germany).
The product is a long-acting version of filgrastim and is likely to be prescribed to appropriate cancer patients undergoing chemotherapy to improve the production of infection-fighting white blood cells.
Sandoz, a Novartis, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for marketing authorization of its proposed biosimilar pegfilgrastim, a long-acting version of supportive oncology care medicine filgrastim. Sandoz is committed to increasing patient access to high-quality biosimilars, with five marketed and seven approved biosimilars in Europe.
The 50-50joint venture was launched in 1984 to fund the global development of Epogen (epoetin alfa) and, over time, was expanded to include Neupogen (filgrastim), Neulasta (pegfilgrastim), Aranesp (darbepoetin alfa), Nplate (romiplostim) and brodalumab.
Over time, the scope of the collaboration was expanded to include NEUPOGEN (filgrastim), Neulasta (pegfilgrastim), Aranesp (darbepoetin alfa), Nplate (romiplostim) and brodalumab.
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) analogue and is employed in IVF because natural G-CSF is suspected to have an important role in oocyte maturation, the ovulation process and endometrial receptivity (13).
The unanimous ruling overturns an appeals court ruling in favor of California-based Amgen that had barred competitor Sandoz from selling its biosimilar of Neupogen (filgrastim) until 6 months after Food and Drug Administration approval.
[11] The frontal cortex and hippocampus were selected as the areas of interest in this study to see filgrastim effects on cholinergic function because these areas receive extensive innervation from cholinergic neurons in the basal forebrain.
In addition, there are no data on potential pro- or anti-inflammatory effects of filgrastim, an analogue of cytokine granulocyte colony-stimulating factor (G-CSF) widely used in the treatment of neutropenia.
The use of granulocyte-colony stimulating factor, such as filgrastim, often is viewed as a "rescue" treatment.